LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio

LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance

Revenue: Q4 of $2.8 billion , up 2% over 2017; Full year of $11.3 billion , up 10% over 2017 Diluted EPS: Q4 of $1.56 ; Full year of $8.61 Adjusted EPS: Q4 of $2.52 , up 11% over 2017; Full year of $11.02 , up 20% over 2017 2019 Adjusted EPS guidance of $11.00 to $11.40 2019 Free Cash Flow guidance

LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE  magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year.

LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019 , and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

LabCorp and Texas Association of Community Health Centers Extend Agreement for LabCorp to Be Exclusive Laboratory for Community Health Centers Across Texas

LabCorp Will Provide Enhanced Laboratory Services, With an Emphasis on Chronic Diseases, for Clinics Serving More Than One Million Patients Annually BURLINGTON, N.C. & AUSTIN, Texas --(BUSINESS WIRE)--Jan. 15, 2019-- LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas